[go: up one dir, main page]

ES2111163T3 - Uso de fosfonatos para el tratamiento de la osteoporosis. - Google Patents

Uso de fosfonatos para el tratamiento de la osteoporosis.

Info

Publication number
ES2111163T3
ES2111163T3 ES93914339T ES93914339T ES2111163T3 ES 2111163 T3 ES2111163 T3 ES 2111163T3 ES 93914339 T ES93914339 T ES 93914339T ES 93914339 T ES93914339 T ES 93914339T ES 2111163 T3 ES2111163 T3 ES 2111163T3
Authority
ES
Spain
Prior art keywords
high potency
day
thirty
potency phosphonate
phosphonate compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93914339T
Other languages
English (en)
Inventor
Marion David Francis
Rogely Waite Boyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Chilcott Pharmaceuticals Inc
Original Assignee
Procter and Gamble Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25422708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2111163(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter and Gamble Pharmaceuticals Inc filed Critical Procter and Gamble Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2111163T3 publication Critical patent/ES2111163T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN METODO PARA AUMENTAR LA MASA OSEA DE UN SER HUMANO O DE CUALQUIER OTRO SUJETO MAMIFERO AFECTADO DE OSTEOPOROSIS, QUE COSISTE EN UN REGIMEN DE ADMINISTRACION DE UN COMPUESTO DE FOSFONATO DE ALTA POTENCIA, DURANTE UN PERIODO DE TRATAMIENTO DE TREINTA (30) DIAS EN DONDE A) DICHO REGIMEN DE ADMINISTRACION DE UN FOSFONATO DE ALTA POTENCIA CONSISTE EN LA ADMINISTRACION SISTEMATICA A DICHO SUJETO DE UN COMPUESTO DE FOSFONATO DE ALTA POTENCIA A UN NIVEL DE 0,00001 MGP/KG A 0,1 MGP/KG POR DIA EN QUE SE ADMINISTRE DICHO COMPUESTO DE FOSFONATO DE ALTA POTENCIA, SIEMPRE Y CUANDO DICHO COMPUESTO DE FOSFONATO DE ALTA POTENCIA SE ADMINISTRA AL MENOS UN DIA DE CADA PERIODO DE TRATAMIENTO DE TREINTA (30) DIAS ANTEDICHO; Y EN DONDE B) DICHO PERIODO DE TRATAMIENTO DE TREINTA (30) DIAS PUEDE IR SEGUIDO DE UN PERIODO DE DESCANSO DE AL MENOS UN DIA.
ES93914339T 1992-06-30 1993-06-04 Uso de fosfonatos para el tratamiento de la osteoporosis. Expired - Lifetime ES2111163T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90660992A 1992-06-30 1992-06-30

Publications (1)

Publication Number Publication Date
ES2111163T3 true ES2111163T3 (es) 1998-03-01

Family

ID=25422708

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93914339T Expired - Lifetime ES2111163T3 (es) 1992-06-30 1993-06-04 Uso de fosfonatos para el tratamiento de la osteoporosis.

Country Status (13)

Country Link
EP (1) EP0648120B1 (es)
JP (2) JP4481368B2 (es)
KR (1) KR950702120A (es)
AT (1) ATE161423T1 (es)
AU (1) AU659329B2 (es)
CA (1) CA2138367C (es)
DE (1) DE69316013T2 (es)
DK (1) DK0648120T3 (es)
ES (1) ES2111163T3 (es)
GR (1) GR3025792T3 (es)
HU (1) HUT70210A (es)
MA (1) MA22915A1 (es)
WO (1) WO1994000129A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727629A1 (fr) * 1994-12-06 1996-06-07 Sanofi Sa Trousse pour cycle de traitement de l'osteoporose
JP3796693B2 (ja) * 1994-12-28 2006-07-12 ガドール エス アー オルパドロネートからなる骨塊同化組成物
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
AU2005227418B2 (en) * 1997-07-22 2008-05-29 Merck Sharp & Dohme Corp. Method for inhibiting bone resorption
AU2007211965B2 (en) * 1997-07-22 2008-05-15 Merck Sharp & Dohme Corp. Alendronate for use in the treatment of osteoporosis
CN1299689C (zh) * 1997-07-22 2007-02-14 默克公司 阿仑膦酸在制备抑制骨吸收药物中的用途
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
PL203087B1 (pl) 2000-06-20 2009-08-31 Novartis Ag Zastosowanie kwasu 1-hydroksy-2-(imidazol-1-ilo)etano-1,1-difosfonowego albo jego farmaceutycznie dopuszczanej soli albo dowolnego hydratu
KR20090029312A (ko) 2002-05-10 2009-03-20 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
AU2007226964B2 (en) * 2006-03-17 2012-03-22 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
ITPA20070034A1 (it) * 2007-10-30 2009-04-30 Tetrapharm S R L Bifosfonati geminali, loro preparazione e loro impiego in campo oncologico.
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
TWI730039B (zh) * 2016-01-29 2021-06-11 日商富士藥品股份有限公司 新穎雙膦酸化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH27078A (en) * 1984-12-21 1993-02-01 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonates
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
DE4011777A1 (de) * 1989-04-14 1990-10-18 Ciba Geigy Ag N-trisubstituierte aminoalkandiphosphonsaeuren

Also Published As

Publication number Publication date
CA2138367C (en) 1998-09-22
CA2138367A1 (en) 1994-01-06
JP4481368B2 (ja) 2010-06-16
AU4403893A (en) 1994-01-24
GR3025792T3 (en) 1998-03-31
DE69316013T2 (de) 1998-07-09
JPH07508278A (ja) 1995-09-14
ATE161423T1 (de) 1998-01-15
MA22915A1 (fr) 1993-12-31
AU659329B2 (en) 1995-05-11
JP2010106042A (ja) 2010-05-13
KR950702120A (ko) 1995-06-19
DK0648120T3 (da) 1998-01-19
HUT70210A (en) 1995-09-28
WO1994000129A1 (en) 1994-01-06
EP0648120A1 (en) 1995-04-19
EP0648120B1 (en) 1997-12-29
DE69316013D1 (de) 1998-02-05

Similar Documents

Publication Publication Date Title
ES2111163T3 (es) Uso de fosfonatos para el tratamiento de la osteoporosis.
ATE189400T1 (de) Knochenwachstumsfördernde zusammensetzung
ES2087061T3 (es) Utilizacion de ribosido o ribotido de aica para la fabricacion de un medicamento contra la crisis cardiaca o el infarto de miocardio en los pacientes que sufren de ateroesclerosis.
CA2124792A1 (en) Methods for the Treatment of Osteoporosis Using Bisphosphonates and Parathyroid Hormone
DK483285A (da) Farmaceutisk praeparat og anvendelsen af samme
MY103212A (en) Zinc-protamine-alpha interferon complex
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
ES2099245T3 (es) Tratamiento de la osteoporosis usando factor de liberacion de hormona de crecimiento (grf) en combinacion con hormona paratiroidea (pth).
ATE211387T1 (de) Oral 1alpha-hydroxyprevitamin d
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
ES2063033T3 (es) Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
EP0365779A3 (en) Cyclic grf-analogs ii
MX9203319A (es) Metodo para la preparacion de cristales de alfa-2 interferona.
ATE118169T1 (de) Arzneistoff-lipid-systeme mit geringer toxizität.
DK0389035T3 (da) Farmaceutisk præparat der indeholder en farmaceutisk egnet bærer og forbindelsen med strukturen (7alfa,17alfa)-17-hydroxy-7-methyl-19-nor-17-pregn-5-(10)-en-20-yn-3-on
DE69429365D1 (de) Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden
RU93058532A (ru) Фармацевтическая композиция для остеоиндукции, способ генерации новой кости
ES2058191T3 (es) Acidos 2-fenil-4-quinolincarboxilicos substituidos.
ES2067864T3 (es) Tratamiento de la hipertension ocular con una combinacion sinergica para administracion ocular.
IT9020020A0 (it) "n,n'-ditrimetossibenzoilpiperazine 2-sostituite, procedimento per la loro preparazione e composizioni terapeutiche che le contengono
ES2046246T3 (es) Composicion terapeutica para combatir el sida.
MX9301879A (es) Medicamento para el tratamiento de la inflamacion de las vias respiratorias
MX174093B (es) 1,1-DIOXIDOS DE 3,4-DIHIDRO-2-ALQUIL-3-OXO-N-ARIL-2H[1] BENZOTIENO[3,2-e]-1,2-TIAZINO-4-CARBOXIAMIDA

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 648120

Country of ref document: ES